You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.
RemunityPRO™ for remodulin: Innovation That Delivers
Intra-page navigation
INTRODUCING THE NEXT-GENERATION PUMP FOR PAH
Learn how RemunityPRO marks the next era in SC pump technology by building on the experience of the first generation of Remunity.
REMUNITYPRO™ IS THE NEXT-GENERATION PUMP
OPTIMIZED WITH INPUT FROM YOU AND YOUR PATIENTS
Building on the small and discreet first generation Remunity® pump, RemunityPRO™ has optimized features designed with input from practitioners and patients.
- User-friendly remote provides step-by-step instructions
- Automated priming and improved connectivity improve ease of use and accessibility
- Streamlined alerts help patients stay on track while reducing disruptions
- Simplified filling and lower flow rate enhance usability
Patients currently on the first generation of Remunity pump are not required to transition to the RemunityPRO pump.
Option for starting patients at home
Lower concentrations of Remodulin, along with the lower flow rates, allow the option to start patients in the convenience of their own home
Innovation that Delivers
CONVENIENCE
Compact and lightweight at just 2” in diameter, 3/4” thick, and 1.7 ounces, RemunityPRO fits effortlessly on a belt or in a pocket. It's easy-to-learn, easy-to-fill, and the self-priming design delivers 72 hours (3 days) of continuous medication.
CONFIDENCE
Built on your valuable feedback, RemunityPro is a reliable and secure choice for your patients. With advanced Bluetooth® , a redesigned remote offering guided instructions, streamlined alerts, and more, RemunityPro provides enhanced confidence in pump therapy.
CARE AND SUPPORT
Both you and your patients benefit from an optimized experience, clear instructions, and robust educational resources, ensuring ongoing support and confidence throughout the pump therapy journey.
A learning platform for healthcare practitioners that offers:
- Demonstration videos and user guides
- Tips and best practices
- Easy troubleshooting and support
- Nurse-specific resources
- Timely updates
- And more
Have additional questions?
Request a United Therapeutics Representative for additional information about Remodulin.
SUPPORT FOR YOUR PATIENTS ON REMODULIN
Aim to improve the Remodulin experience
UNITED THERAPEUTICS CARES
United Therapeutics Cares connects patients with specialists, including Specialty Pharmacy support, for education on access, affordability, and treatment from day one.
Our team provides personalized, ongoing support throughout their therapy.
Visit United Therapeutics Cares to learn more and enroll your patient today.
Call United Therapeutics Cares at 1-844-864-84371-844-864-8437, Monday through Friday, 8:30 am - 7 pm ET.
LEARN MORE
MyRemodulin.com
For patients about to start or currently on therapy, MyRemodulin.com is a personalized website experience that offers information specific to their route of administration, their pump, and where they are on their journey.
Patients have access to pump user guides, encouraging videos from other PAH patients, helpful tips for an improved experience, and much more.
WATCH THE VIDEORemodulin social community
Remodulin has an active social community on Facebook, Instagram, and YouTube.
Guide your patients to these platforms to connect with other patients with PAH.
Click an icon to visit us on social:
Considering RemunityPRO for your patients on SC Remodulin?
Watch the user guide videos or download the RemunityPRO User Guide.
For Important Safety Information on RemunityPRO, please click here.
SC=subcutaneous; PAH=pulmonary arterial hypertension.
Remodulin® (treprostinil) Injection
Important Safety Information for Remodulin
Warnings and Precautions
- Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
- Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
- Titrate slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function.
- Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
- Remodulin inhibits platelet aggregation and increases the risk of bleeding.
Adverse Reactions
- In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).
Drug Interactions
- Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
Specific Populations
- In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
- Safety and effectiveness of Remodulin in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.
REMISIhcpFEB2025
Please see accompanying Full Prescribing Information for Remodulin.
For additional information, visit www.RemodulinPro.com or call Customer Service at 1-844-UNITHER (1-844-864-8437).
For additional information, visit www.RemodulinPro.com or call Customer Service at 1-844-UNITHER (1-844-864-8437).
Remodulin® (treprostinil) Injection
Important Safety Information for Remodulin
Warnings and Precautions
- Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
- Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
- Titrate slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function.
- Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
- Remodulin inhibits platelet aggregation and increases the risk of bleeding.
Adverse Reactions
- In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).
Drug Interactions
- Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
Specific Populations
- In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
- Safety and effectiveness of Remodulin in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.
REMISIhcpFEB2025
Please see accompanying Full Prescribing Information for Remodulin.
For additional information, visit www.RemodulinPro.com or call Customer Service at 1-844-UNITHER (1-844-864-8437).
References: 1. RemunityPRO User Guide. Research Triangle Park, NC: United Therapeutics Corporation; 2025. 2. Remunity User Guide. Research Triangle Park, NC: United Therapeutics Corporation; 2023.
